Subcutaneous administration of bortezomib: a new reality in the treatment of patients with multiple myeloma

Detalhes bibliográficos
Autor(a) principal: Santos, Rui
Data de Publicação: 2013
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.31877/on.2013.22.04
Resumo: Subcutaneous administration of bortezomib was approved by EMA in September 2012 for treatment of patients in first-line and relapsed multiple myeloma.This article update seeks to present the experience of an Autonomous Clinical Oncology Unit at Hospital Fernando Fonseca, EPE, with administration of this new formulation and the results which demonstrated a similarity with the current literature. These results showed the same efficacy as the form of intravenous administration with significant reduction of the occurrence of peripheral neuropathy which is the main dose-limiting toxicity, compromising the quality of life of these patients.
id RCAP_4ff8af8425d64b74ec9bab19b3555714
oai_identifier_str oai:oai.onco.news:article/175
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Subcutaneous administration of bortezomib: a new reality in the treatment of patients with multiple myelomaAdministração subcutânea de bortezomib: uma nova realidade no tratamento de doentes com mieloma múltiploMieloma MúltiploNeuropatia PeriféricaBortezomibMultiple MyelomaPeripheral NeuropathyBortezomibSubcutaneous administration of bortezomib was approved by EMA in September 2012 for treatment of patients in first-line and relapsed multiple myeloma.This article update seeks to present the experience of an Autonomous Clinical Oncology Unit at Hospital Fernando Fonseca, EPE, with administration of this new formulation and the results which demonstrated a similarity with the current literature. These results showed the same efficacy as the form of intravenous administration with significant reduction of the occurrence of peripheral neuropathy which is the main dose-limiting toxicity, compromising the quality of life of these patients.A administração subcutânea (SC) de bortezomib foi aprovada pela EMA em Setembro de 2012 no tratamento de doentes em primeira linha e em recidiva de mieloma múltiplo.O presente artigo de actualização pretende dar a conhecer a experiência da Unidade Clínica Autónoma de Oncologia do Hospital Fernando Fonseca, EPE, com a administração desta nova formulação, tendo os resultados obtidos demonstrado uma similaridade com a actual literatura. Estes evidenciam a mesma eficácia que a forma de administração endovenosa (EV) e uma redução significativa da ocorrência de neuropatia periférica, principal toxicidade limitante de dose e comprometedora da qualidade de vida destes doentes.AEOP – Associação de Enfermagem Oncológica Portuguesa2013-11-10info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.31877/on.2013.22.04https://doi.org/10.31877/on.2013.22.04Onco.news; No. 22 (2013): Onco.News Journal; 32-35Onco.News; N.º 22 (2013): Revista Onco.News; 32-352183-69141646-7868reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://onco.news/index.php/journal/article/view/175https://onco.news/index.php/journal/article/view/175/181Direitos de Autor (c) 2023 Rui Santosinfo:eu-repo/semantics/openAccessSantos, Rui2024-03-16T07:55:26Zoai:oai.onco.news:article/175Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T04:01:24.697641Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Subcutaneous administration of bortezomib: a new reality in the treatment of patients with multiple myeloma
Administração subcutânea de bortezomib: uma nova realidade no tratamento de doentes com mieloma múltiplo
title Subcutaneous administration of bortezomib: a new reality in the treatment of patients with multiple myeloma
spellingShingle Subcutaneous administration of bortezomib: a new reality in the treatment of patients with multiple myeloma
Santos, Rui
Mieloma Múltiplo
Neuropatia Periférica
Bortezomib
Multiple Myeloma
Peripheral Neuropathy
Bortezomib
title_short Subcutaneous administration of bortezomib: a new reality in the treatment of patients with multiple myeloma
title_full Subcutaneous administration of bortezomib: a new reality in the treatment of patients with multiple myeloma
title_fullStr Subcutaneous administration of bortezomib: a new reality in the treatment of patients with multiple myeloma
title_full_unstemmed Subcutaneous administration of bortezomib: a new reality in the treatment of patients with multiple myeloma
title_sort Subcutaneous administration of bortezomib: a new reality in the treatment of patients with multiple myeloma
author Santos, Rui
author_facet Santos, Rui
author_role author
dc.contributor.author.fl_str_mv Santos, Rui
dc.subject.por.fl_str_mv Mieloma Múltiplo
Neuropatia Periférica
Bortezomib
Multiple Myeloma
Peripheral Neuropathy
Bortezomib
topic Mieloma Múltiplo
Neuropatia Periférica
Bortezomib
Multiple Myeloma
Peripheral Neuropathy
Bortezomib
description Subcutaneous administration of bortezomib was approved by EMA in September 2012 for treatment of patients in first-line and relapsed multiple myeloma.This article update seeks to present the experience of an Autonomous Clinical Oncology Unit at Hospital Fernando Fonseca, EPE, with administration of this new formulation and the results which demonstrated a similarity with the current literature. These results showed the same efficacy as the form of intravenous administration with significant reduction of the occurrence of peripheral neuropathy which is the main dose-limiting toxicity, compromising the quality of life of these patients.
publishDate 2013
dc.date.none.fl_str_mv 2013-11-10
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.31877/on.2013.22.04
https://doi.org/10.31877/on.2013.22.04
url https://doi.org/10.31877/on.2013.22.04
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://onco.news/index.php/journal/article/view/175
https://onco.news/index.php/journal/article/view/175/181
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2023 Rui Santos
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2023 Rui Santos
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv AEOP – Associação de Enfermagem Oncológica Portuguesa
publisher.none.fl_str_mv AEOP – Associação de Enfermagem Oncológica Portuguesa
dc.source.none.fl_str_mv Onco.news; No. 22 (2013): Onco.News Journal; 32-35
Onco.News; N.º 22 (2013): Revista Onco.News; 32-35
2183-6914
1646-7868
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138187695620096

Registros relacionados